Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …

Abstract Background Acquired Hemophilia A (AHA) is a rare autoimmune disorder
associated with the development of autoantibodies against factor VIII (FVIII). Although …

Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia
A with or without neutralizing antibodies (inhibitors) against factor VIII (FVIII). Here, we …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies
inhibiting coagulation factor VIII. For hemostatic treatment bypassing agents (recombinant …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Objective: Unusual setting of medical care Background: Acquired hemophilia A (AHA) is a
rare hemorrhagic disorder that is caused by producing autoantibodies against factor VIII. It is …

Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease
caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two …

Abstract Introduction Acquired haemophilia A (AHA) is a rare and potentially life‐threatening
bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII) …

ABSTRACT Acquired Hemophilia A (AHA) is a rare, life-threatening bleeding disorder from
autoantibodies against clotting factor VIII. These autoantibodies occur with increasing …

Abstract Introduction Acquired hemophilia A (AHA) is a severe bleeding disorder due to
autoantibodies against factor VIII (FVIII) with high morbidity/mortality from bleeding and …